^
    Back
    Association details:
    Biomarker:PTPN11 mutations + MCL1 overexpression
    Cancer:Acute Myelogenous Leukemia
    Drug:idasanutlin (RG7388) (MDM2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2018
    Title:

    Biomarkers Predicting Venetoclax Sensitivity and Strategies for Venetoclax Combination Treatment

    Published date:
    11/01/2018
    Excerpt:
    Samples harboring PTPN11 mutations demonstrated high MCL1 expression, and PTPN11 mutant-transduced cells remain sensitive to Idasanutlin, which was previously shown to downregulate MCL1 expression.
    DOI:
    https://doi.org/10.1182/blood-2018-175